HomeostasisNCT07602114
Observational Study of Electrical Impedance Tomography for Non-Invasive Assessment of Cerebral Autoregulation in Neurocritical Patients
An observational study of Homeostasis, run by Xijing Hospital at 1 site in China.
Trial summary
This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Homeostasis
- What is being tested?
- Non-invasive cerebral Electrical Impedance Tomography (EIT) monitoring
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 25 Aug 2026to 30 May 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of adult neurocritical care inpatients admitted to the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, the First Affiliated Hospital of Air Force Military Medical University. Eligible participants are patients aged ≥18 years with severe acute cerebrovascular diseases, severe traumatic brain injury and other critical central nervous system disorders who require NICU admission and routine invasive intracranial pressure and mean arterial pressure monitoring, forming a single-center prospective observational cohort with consecutive enrollment.
Who may be able to join
- Aged ≥18 years old
- Diagnosed with acute intracerebral hemorrhage, subarachnoid hemorrhage or ischemic stroke, admitted to the Neurosurgical Intensive Care Unit
- Receiving routine invasive monitoring of intracranial pressure (ICP) and mean arterial pressure (MAP)
- Written informed consent obtained from the legally authorized representative
Who cannot join
- Severe scalp damage, infection or skull defect affecting electrode placement
- Craniotomy history with metal implants interfering with EIT signal acquisition Pregnancy
- Terminal critical illness with estimated survival <24 hours
- Severe coagulation dysfunction or confirmed allergy to electrode materials
- Unavailable for ≥2-hour continuous valid monitoring data collection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xijing Hospital, Air Force Medical University
Xi'an, Shaanxi, 710032
zhu, +8613259705127, 13259705127@163.com
About this study
Official title: A Clinical Study of Non-Invasive Assessment of Cerebral Autoregulation Using Electrical Impedance Tomography
This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study aims to evaluate whether non-invasive Electrical Impedance Tomography (EIT) can reliably assess cerebral blood flow autoregulation in neurocritically ill participants, by comparing EIT-derived parameters with the current gold-standard invasive index PRx.
Cerebral blood flow autoregulation helps maintain stable brain perfusion in critically ill neurological patients. Impaired autoregulation raises the risk of secondary brain injury. The current standard evaluation requires invasive intracranial pressure monitoring, which carries risks of infection, bleeding, and tissue damage. EIT is a non-invasive, radiation-free bedside monitoring technique that uses scalp electrodes to measure real-time changes related to cerebral blood flow, with no additional harm to participants.
Read more
Adult participants admitted to the neurosurgical intensive care unit who require routine invasive intracranial pressure monitoring will be enrolled, with informed consent provided by legal guardians. All participants receive standard clinical care as prescribed by current medical guidelines; no extra experimental treatments, drugs, or invasive procedures are applied for this study.
During the study, invasive monitoring data and non-invasive EIT brain monitoring data will be collected simultaneously. Researchers will analyze the correlation and consistency between EIT-derived parameters and the gold-standard index.
This study has received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital, Air Force Military Medical University. All participant information is anonymized to protect privacy, and adverse events will be recorded and reported in accordance with regulatory requirements. The results are expected to support a safe, non-invasive monitoring method for cerebral blood flow autoregulation in neurocritical care.
Read the detailed description
Background and Rationale Cerebral autoregulation (CA) is the ability of the cerebrovascular system to maintain relatively constant cerebral blood flow when cerebral perfusion pressure is extremely high or low. In neurocritical patients with acute intracerebral hemorrhage, subarachnoid hemorrhage, or ischemic stroke, impaired CA is closely associated with secondary brain injury, intracranial hypertension, neurological deterioration, and poor outcomes. The pressure reactivity index (PRx), calculated as the moving Pearson correlation between invasively measured intracranial pressure (ICP) and mean arterial pressure (MAP), is the current gold standard for bedside assessment of CA. However, invasive ICP monitoring requires surgical placement of an intraventricular or intraparenchymal catheter, which carries risks of infection, hemorrhage, cerebrospinal fluid leakage, and tissue damage, and requires specialized expertise and intensive care resources, limiting widespread use.
Electrical impedance tomography (EIT) is a non-invasive, radiation-free, real-time biomedical imaging technique that measures regional changes in bioimpedance, which reflect variations in cerebral blood volume and tissue perfusion. A custom-built cerebral EIT system (EC100-PRO) has been developed by the research team. It uses 16 scalp electrodes placed in a ring configuration to continuously acquire impedance signals. Through standardized signal processing and image reconstruction algorithms, EIT-derived parameters that track cardiac-synchronous cerebral blood volume pulsations are generated. Preclinical and pilot clinical data indicate that these EIT-derived parameters correlate with changes in cerebral perfusion and autoregulatory status. This study aims to validate the agreement between EIT-derived parameters and the reference standard PRx, thereby establishing a non-invasive, continuous alternative for CA monitoring in neurocritical care.
Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.
All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.
Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.
Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.
Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.
All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.
Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.
Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.
- Conditions
- Homeostasis
- Being tested
- Non-invasive cerebral Electrical Impedance Tomography (EIT) monitoring
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-invasive cerebral Electrical Impedance Tomography (EIT) monitoringOther
Non-invasive real-time cerebral physiological monitoring performed by attaching standard scalp electrodes and collecting continuous cerebral bio-impedance signals via an Electrical Impedance Tomography (EIT) system. This monitoring is conducted synchronously with routine invasive intracranial pressure and arterial blood pressure monitoring in neurocritical care. It is purely an observational measurement procedure without any therapeutic intervention or modification to standard clinical treatment for participants, aiming to derive EIT-based parameters for evaluating cerebral blood flow autoregulation function.
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation and consistency between EIT-derived parameters and pressure reactivity index (PRx) for cerebral blood flow autoregulation assessment
To evaluate the linear correlation (Pearson correlation coefficient) and agreement (Bland-Altman analysis) between non-invasive EIT-derived parameters and the invasive gold-standard PRx index in assessing cerebral blood flow autoregulation among neurocritically ill patients.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start25 Aug 2026
- Primary completion28 Feb 2028 (estimated)
- Study completion30 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HomeostasisStudies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07602114
- Sponsor's protocol ID
- KY20262178-C-1
- Status last verified
- Sep 2026
- First submitted
- 17 May 2026
- Last updated
- 26 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared with external researchers due to privacy protection and institutional data security regulations. Aggregated statistical results will be published in peer-reviewed journals.
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study of Non-Invasive Assessment of Cerebral Autoregulation Using Electrical Impedance Tomography
- ClinicalTrials.gov ID
- NCT07602114
- Acronym / sponsor ID
- KY20262178-C-1
- Conditions
- Homeostasis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 25 Aug 2026 (actual)
- Primary completion
- 28 Feb 2028 (estimated)
- Study completion
- 30 May 2028 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study aims to evaluate whether non-invasive Electrical Impedance Tomography (EIT) can reliably assess cerebral blood flow autoregulation in neurocritically ill participants, by comparing EIT-derived parameters with the current gold-standard invasive index PRx.
Cerebral blood flow autoregulation helps maintain stable brain perfusion in critically ill neurological patients. Impaired autoregulation raises the risk of secondary brain injury. The current standard evaluation requires invasive intracranial pressure monitoring, which carries risks of infection, bleeding, and tissue damage. EIT is a non-invasive, radiation-free bedside monitoring technique that uses scalp electrodes to measure real-time changes related to cerebral blood flow, with no additional harm to participants.
Adult participants admitted to the neurosurgical intensive care unit who require routine invasive intracranial pressure monitoring will be enrolled, with informed consent provided by legal guardians. All participants receive standard clinical care as prescribed by current medical guidelines; no extra experimental treatments, drugs, or invasive procedures are applied for this study.
During the study, invasive monitoring data and non-invasive EIT brain monitoring data will be collected simultaneously. Researchers will analyze the correlation and consistency between EIT-derived parameters and the gold-standard index.
This study has received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital, Air Force Military Medical University. All participant information is anonymized to protect privacy, and adverse events will be recorded and reported in accordance with regulatory requirements. The results are expected to support a safe, non-invasive monitoring method for cerebral blood flow autoregulation in neurocritical care.
Detailed description
Background and Rationale Cerebral autoregulation (CA) is the ability of the cerebrovascular system to maintain relatively constant cerebral blood flow when cerebral perfusion pressure is extremely high or low. In neurocritical patients with acute intracerebral hemorrhage, subarachnoid hemorrhage, or ischemic stroke, impaired CA is closely associated with secondary brain injury, intracranial hypertension, neurological deterioration, and poor outcomes. The pressure reactivity index (PRx), calculated as the moving Pearson correlation between invasively measured intracranial pressure (ICP) and mean arterial pressure (MAP), is the current gold standard for bedside assessment of CA. However, invasive ICP monitoring requires surgical placement of an intraventricular or intraparenchymal catheter, which carries risks of infection, hemorrhage, cerebrospinal fluid leakage, and tissue damage, and requires specialized expertise and intensive care resources, limiting widespread use.
Electrical impedance tomography (EIT) is a non-invasive, radiation-free, real-time biomedical imaging technique that measures regional changes in bioimpedance, which reflect variations in cerebral blood volume and tissue perfusion. A custom-built cerebral EIT system (EC100-PRO) has been developed by the research team. It uses 16 scalp electrodes placed in a ring configuration to continuously acquire impedance signals. Through standardized signal processing and image reconstruction algorithms, EIT-derived parameters that track cardiac-synchronous cerebral blood volume pulsations are generated. Preclinical and pilot clinical data indicate that these EIT-derived parameters correlate with changes in cerebral perfusion and autoregulatory status. This study aims to validate the agreement between EIT-derived parameters and the reference standard PRx, thereby establishing a non-invasive, continuous alternative for CA monitoring in neurocritical care.
Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.
All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.
Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.
Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.
Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.
All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.
Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.
Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of adult neurocritical care inpatients admitted to the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, the First Affiliated Hospital of Air Force Military Medical University. Eligible participants are patients aged ≥18 years with severe acute cerebrovascular diseases, severe traumatic brain injury and other critical central nervous system disorders who require NICU admission and routine invasive intracranial pressure and mean arterial pressure monitoring, forming a single-center prospective observational cohort with consecutive enrollment.
Key inclusion criteria (4 listed)
- Aged ≥18 years old
- Diagnosed with acute intracerebral hemorrhage, subarachnoid hemorrhage or ischemic stroke, admitted to the Neurosurgical Intensive Care Unit
- Receiving routine invasive monitoring of intracranial pressure (ICP) and mean arterial pressure (MAP)
- Written informed consent obtained from the legally authorized representative
Key exclusion criteria (5 listed)
- Severe scalp damage, infection or skull defect affecting electrode placement
- Craniotomy history with metal implants interfering with EIT signal acquisition Pregnancy
- Terminal critical illness with estimated survival <24 hours
- Severe coagulation dysfunction or confirmed allergy to electrode materials
- Unavailable for ≥2-hour continuous valid monitoring data collection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-invasive cerebral Electrical Impedance Tomography (EIT) monitoringNon-invasive real-time cerebral physiological monitoring performed by attaching standard scalp electrodes and collecting continuous cerebral bio-impedance signals via an Electrical Impedance Tomography (EIT) system. This monitoring is conducted synchronously with routine invasive intracranial pressure and arterial blood pressure monitoring in neurocritical care. It is purely an observational measurement procedure without any therapeutic intervention or modification to standard clinical treatment for participants, aiming to derive EIT-based parameters for evaluating cerebral blood flow autoregulation function. | Other | – |
Primary outcome
Correlation and consistency between EIT-derived parameters and pressure reactivity index (PRx) for cerebral blood flow autoregulation assessment
Time frame: Through study completion, an average of 1 year
To evaluate the linear correlation (Pearson correlation coefficient) and agreement (Bland-Altman analysis) between non-invasive EIT-derived parameters and the invasive gold-standard PRx index in assessing cerebral blood flow autoregulation among neurocritically ill patients.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared with external researchers due to privacy protection and institutional data security regulations. Aggregated statistical results will be published in peer-reviewed journals.
Related trials for Homeostasis
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Not yet recruitingPhase 2
N-Acetylcysteine for Bipolar and Alcohol Use Disorders
Bipolar Disorder, Alcohol Use Disorder
RecruitingObservational study
CoMind Early Feasibility Study
Intracranial Pressure, Intracranial Pressure Changes
Not yet recruiting
Lily's Grace Temporal Interference
Epilepsy
Not yet recruitingObservational study
Continuous Blood Pressure Variability and Small Vessel Disease in Acute Ischemic Stroke
Ischemic Stroke, Acute, Blood Pressure Variability
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Homeostasis, run by Xijing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation and consistency between EIT-derived parameters and pressure reactivity index (PRx) for cerebral blood flow autoregulation assessment (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.